NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 56.70

+5.1%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (79)	8/2/2006 8:36:56 AM
From: david nordic	Read Replies (1) of 507

Novo Nordisk files suit against Pfizer PrintDisable live quotesRSSDigg itDel.icio.usBy Angela Moore Last Update: 8:17 AM ET Aug 2, 2006 NEW YORK (MarketWatch) -- Novo Nordisk (NVO : Novo-Nordisk A/S News , chart, profile, more Last: 0.000.000.00% PFE0.00, 0.00, 0.0%) , charging that Pfizer's Exubera infringes on patents on inhaled insulin and diabetes treatments owned by Novo Nordisk. Princeton, N.J.-based Novo Nordisk said Pfizer "willfully infringed" on the patents and seeks compensatory damages. Novo Nordisk said it plans to file a motion for preliminary injunction seeking a court order that would prohibit Pfizer from "continuing its unlawful conduct" while the lawsuit is in progress. Earlier this year, the Food and Drug Administration approved the U.S.'s first inhaled insulin product, Exubera. It was co-developed by Pfizer and Nektar Therapeutics.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next